These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 12796128)

  • 1. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin.
    Anand SS; Yusuf S; Pogue J; Ginsberg JS; Hirsh J;
    Circulation; 2003 Jun; 107(23):2884-8. PubMed ID: 12796128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
    Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of post-procedural aPTT in patients with ST-elevation myocardial infarction treated with primary PCI.
    Kikkert WJ; van Nes SH; Lieve KV; Dangas GD; van Straalen J; Vis M; Baan J; Koch KT; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP
    Thromb Haemost; 2013 May; 109(5):961-70. PubMed ID: 23446910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physician-guided treatment compared with a heparin protocol for deep vein thrombosis.
    Elliott CG; Hiltunen SJ; Suchyta M; Hull RD; Raskob GE; Pineo GF; Jensen RL; Yeates S; Kitterman N
    Arch Intern Med; 1994 May; 154(9):999-1004. PubMed ID: 8179457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
    Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S;
    Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
    Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
    Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial.
    Lopes RD; Alexander KP; Marcucci G; White HD; Spinler S; Col J; Aylward PE; Califf RM; Mahaffey KW
    Eur Heart J; 2008 Aug; 29(15):1827-33. PubMed ID: 18519426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays.
    Baker BA; Adelman MD; Smith PA; Osborn JC
    Arch Intern Med; 1997 Nov; 157(21):2475-9. PubMed ID: 9385299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of bleeding complications associated with glycoprotein IIb/IIIa receptors blockade in patients with high-risk acute coronary syndromes: insights from the PRISM-PLUS study.
    Huynh T; Piazza N; DiBattiste PM; Snapinn SM; Wan Y; Pharand C; Theroux P
    Int J Cardiol; 2005 Apr; 100(1):73-8. PubMed ID: 15820288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL
    Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
    Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
    Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
    Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
    Karthikeyan G; Mehta SR; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes.
    Melloni C; Alexander KP; Chen AY; Newby LK; Roe MT; Allen LaPointe NM; Pollack CV; Gibler WB; Ohman EM; Peterson ED;
    Am Heart J; 2008 Aug; 156(2):209-15. PubMed ID: 18657648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated clotting time differential is a superior method of monitoring anticoagulation following coronary angioplasty.
    Pitney MR; Kelly SA; Allan RM; Giles RW; McCredie M; Walsh WF
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):145-50. PubMed ID: 8808069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative.
    Wang TY; Chen AY; Peterson ED; Becker RC; Gibler WB; Ohman EM; Roe MT
    Eur Heart J; 2008 May; 29(9):1103-9. PubMed ID: 18353757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
    Slaughter MS; Naka Y; John R; Boyle A; Conte JV; Russell SD; Aaronson KD; Sundareswaran KS; Farrar DJ; Pagani FD
    J Heart Lung Transplant; 2010 Jun; 29(6):616-24. PubMed ID: 20400335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.